XBiotech Statistics
Total Valuation
XBiotech has a market cap or net worth of $69.21 million. The enterprise value is -$40.32 million.
| Market Cap | 69.21M |
| Enterprise Value | -40.32M |
Important Dates
The last earnings date was Thursday, August 13, 2026.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
XBiotech has 30.49 million shares outstanding. The number of shares has increased by 0.04% in one year.
| Current Share Class | 30.49M |
| Shares Outstanding | 30.49M |
| Shares Change (YoY) | +0.04% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 25.09% |
| Owned by Institutions (%) | 6.70% |
| Float | 22.84M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.55 |
| P/TBV Ratio | 0.55 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 33.15
| Current Ratio | 33.15 |
| Quick Ratio | 32.75 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -29.94% and return on invested capital (ROIC) is -250.55%.
| Return on Equity (ROE) | -29.94% |
| Return on Assets (ROA) | -19.30% |
| Return on Invested Capital (ROIC) | -250.55% |
| Return on Capital Employed (ROCE) | -37.01% |
| Weighted Average Cost of Capital (WACC) | 8.91% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$518,770 |
| Employee Count | 87 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, XBiotech has paid $273,000 in taxes.
| Income Tax | 273,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -28.25% in the last 52 weeks. The beta is 0.85, so XBiotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.85 |
| 52-Week Price Change | -28.25% |
| 50-Day Moving Average | 2.31 |
| 200-Day Moving Average | 2.40 |
| Relative Strength Index (RSI) | 45.62 |
| Average Volume (20 Days) | 30,876 |
Short Selling Information
The latest short interest is 325,403, so 1.07% of the outstanding shares have been sold short.
| Short Interest | 325,403 |
| Short Previous Month | 281,470 |
| Short % of Shares Out | 1.07% |
| Short % of Float | 1.42% |
| Short Ratio (days to cover) | 8.04 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -48.22M |
| Pretax Income | -44.86M |
| Net Income | -45.13M |
| EBITDA | -46.78M |
| EBIT | -48.22M |
| Earnings Per Share (EPS) | -$1.48 |
Balance Sheet
The company has $109.53 million in cash and no debt, with a net cash position of $109.53 million or $3.59 per share.
| Cash & Cash Equivalents | 109.53M |
| Total Debt | n/a |
| Net Cash | 109.53M |
| Net Cash Per Share | $3.59 |
| Equity (Book Value) | 128.46M |
| Book Value Per Share | 4.21 |
| Working Capital | 107.81M |
Cash Flow
In the last 12 months, operating cash flow was -$40.70 million and capital expenditures -$144,000, giving a free cash flow of -$40.84 million.
| Operating Cash Flow | -40.70M |
| Capital Expenditures | -144,000 |
| Depreciation & Amortization | 1.44M |
| Net Borrowing | n/a |
| Free Cash Flow | -40.84M |
| FCF Per Share | -$1.34 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
XBiotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.04% |
| Shareholder Yield | -0.04% |
| Earnings Yield | -64.09% |
| FCF Yield | -57.99% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |